Literature DB >> 22844354

Advantages of the quenching probe method over other PCR-based methods for detection of the JAK2 V617F mutation.

Aya Ono1, Yuki Okuhashi, Yusuke Takahashi, Mai Itoh, Nobuo Nara, Shuji Tohda.   

Abstract

The detection of a V617F mutation (G to T exchange at nucleotide 1,849) in the JAK2 gene is crucial for the diagnosis of myeloproliferative neoplasms (MPN) such as polycythemia vera. Although sequence analysis is the standard method for detection, it is not suitable for clinical examinations due to the requirement of expensive equipment. In this study, we evaluated the efficiencies of four PCR-based methods to detect JAK2 V617F: allele-specific PCR (AS-PCR), PCR-restriction fragment length polymorphism (PCR-RFLP), high-resolution melting analysis (HRM) and the quenching probe method (QP). The HEL cell line, which harbors a homozygous JAK2 V617F mutation, as well as bone marrow samples from 16 MPN patients and normal control samples, were used in this assessment. The sensitivity of the detection limit of all four methods was also examined using samples of HEL cells mixed in a variety of ratios with cells containing wild-type JAK2. The results of all four methods were found to be concordant. AS-PCR was shown to be the most sensitive; however, it produced false positive results. Although PCR-RFLP demonstrated high specificity, it was time consuming. By contrast, results were obtained using HRM and QP in only 2 h. It was easier to recognize the curves derived from the mutant allele obtained using QP. QP is also suitable for the rough estimation of allele burden. JAK2 V617F assays are mainly used for diagnosis at presentation in clinical settings. We therefore conclude that in situations where high sensitivity is not required, QP is the preferable method for the detection of JAK2 V617F. To the best of our knowledge, this is the first report to demonstrate the efficiency of the QP method for the detection of JAK2 V617F using a standard thermal cycler.

Entities:  

Year:  2012        PMID: 22844354      PMCID: PMC3402723          DOI: 10.3892/ol.2012.741

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  7 in total

1.  Fully automated and super-rapid system for the detection of JAK2V617F mutation.

Authors:  Ruriko Tanaka; Junya Kuroda; William Stevenson; Eishi Ashihara; Takayuki Ishikawa; Tomohiko Taki; Yutaka Kobayashi; Yuri Kamitsuji; Eri Kawata; Miki Takeuchi; Yoshihide Murotani; Asumi Yokota; Mitsuharu Hirai; Satoshi Majima; Masafumi Taniwaki; Taira Maekawa; Shinya Kimura
Journal:  Leuk Res       Date:  2008-03-06       Impact factor: 3.156

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.

Authors:  Thomas Horn; Marcus Kremer; Tobias Dechow; Walther M Pfeifer; Birgit Geist; Michael Perker; Justus Duyster; Leticia Quintanilla-Martinez; Falko Fend
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

4.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

6.  Fluorescein-labeled oligonucleotides for real-time pcr: using the inherent quenching of deoxyguanosine nucleotides.

Authors:  A O Crockett; C T Wittwer
Journal:  Anal Biochem       Date:  2001-03-01       Impact factor: 3.365

7.  Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.

Authors:  Tze-Kiong Er; Sheng-Fung Lin; Jan-Gowth Chang; Li-Ling Hsieh; Shu-Kai Lin; Li-Hsuan Wang; Chin-Wen Lin; Chao-Sung Chang; Ta-Chih Liu
Journal:  Clin Chim Acta       Date:  2009-07-10       Impact factor: 3.786

  7 in total
  2 in total

1.  Validating the Sensitivity of High-Resolution Melting Analysis for JAK2 V617F Mutation in the Clinical Setting.

Authors:  Chien-Yu Lin; Cheng-Mao Ho; Gevorg Tamamyan; Shu-Fen Yang; Ching-Tien Peng; Jan-Gowth Chang
Journal:  J Clin Lab Anal       Date:  2016-05-12       Impact factor: 2.352

2.  Establishment of a quenching probe method for detection of NPM1 mutations in acute myeloid leukemia cells.

Authors:  Noriko Kawaguchi-Ihara; Mai Itoh; Ikuo Murohashi; Shuji Tohda
Journal:  Oncol Lett       Date:  2016-02-11       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.